SCHEMBL5363022

SCHEMBL5363022

Cc1ccccc1NC(=S)N/N=C/c1cc([N+](=O)[O-])cc([N+](=O)[O-])c1O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.56
KDM4E B2RXH2 7/20 0.56
L3MBTL1 Q9Y468 5/20 0.56
GAA P10253 5/20 0.56
NPC1 O15118 2/20 0.56
KDM4A O75164 1/20 0.56
KDM4C Q9H3R0 1/20 0.56
LMNA P02545 8/20 0.55
HTT P42858 3/20 0.55
ALDH1A1 P00352 2/20 0.55
MEN1 O00255 6/20 0.53
KMT2A Q03164 6/20 0.53
TDP1 Q9NUW8 4/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
TNF P01375 2/20 0.53
NOD1 Q9Y239 2/20 0.53
CASP3 P42574 2/20 0.53
SENP8 Q96LD8 2/20 0.53
SENP7 Q9BQF6 2/20 0.53
SENP6 Q9GZR1 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5363026 1.00 MAPT (0.56) MAPTKDM4EL3MBTL1GAANPC1
SCHEMBL5361265 0.87 MAPT (0.61) MAPTKDM4EL3MBTL1GAAKDM4A
SCHEMBL5361260 0.87 MAPT (0.61) MAPTKDM4EL3MBTL1GAAKDM4A
SCHEMBL5179613 0.76 LMNA (0.60) MAPTKDM4EL3MBTL1GAANPC1
SCHEMBL5179611 0.76 LMNA (0.60) MAPTKDM4EL3MBTL1GAANPC1
SCHEMBL8266121 0.73 MAPT (0.65) MAPTKDM4EL3MBTL1GAANPC1
SCHEMBL13401793 0.72 MEN1 (0.67) MAPTKDM4EL3MBTL1GAALMNA
SCHEMBL19334398 0.72 MAPT (0.58) MAPTKDM4EL3MBTL1GAAKDM4A
Trinitrophenol SCHEMBL9443183 0.70 GPR35 (0.71) MAPTKDM4EGAANPC1LMNA
Trinitrophenol SCHEMBL31588165 0.70 GPR35 (0.71) MAPTKDM4EGAANPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058990-A1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION 2004-03-25 US claimed
US-7241783-B2 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION (US) 2007-07-10 US disclosed
EP-1349613-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2005-09-21 EP disclosed
US-20040058990-A1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION 2004-03-25 US disclosed
EP-1349613-A2 THROMBOPOIETIN MIMETICS SmithKline Beecham Corporation (US) 2003-10-08 EP disclosed
WO-2002049413-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2002-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058990-A1 Thrombopoietin mimetics MPL, THPO, TEK MAPT 4635/4885KDM4E 3460/4885L3MBTL1 812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.